Efgartigimod around surgery for myasthenia gravis with thymoma
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests the drug efgartigimod given before and after surgery for people with myasthenia gravis and a thymoma. The goal is to see if it helps improve symptoms and recovery around the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and expected to live more than a year.
- You have myasthenia gravis (muscle weakness) with a positive AChR antibody test.
- Your myasthenia gravis severity is moderate (MGFA types II to IV).
- A CT scan shows a thymoma that is not spread to distant organs (stages I–IVa).
- You are healthy enough for surgery (ASA class 1 or 2) and have good organ function.
- You have not had open chest surgery before and are planning to have thymoma removal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This study tests whether continuing efgartigimod after a myasthenia gravis crisis helps keep symptoms under control and prevent future flare-ups. It is for people who have already responded to one round of this treatment.
This study tests a new combination treatment for generalized myasthenia gravis. It combines two medications to help reduce muscle weakness and improve your daily life.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.